PPBT VS NRXP Stock Comparison
Performance
PPBT10/100
10/100
PPBT returned -52.51% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
NRXP10/100
10/100
NRXP returned -62.74% in the last 12 months. Based on SPY's performance of -21.23%, its performance is below average giving it a score of 10 of 100.
Technicals
PPBT11/100
11/100
PPBT receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
NRXP64/100
64/100
NRXP receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.
Earnings
PPBT10/100
10/100
PPBT has missed earnings 7 times in the last 20 quarters.
NRXP49/100
49/100
NRXP has missed earnings 2 times in the last 20 quarters.
Profit
PPBT11/100
11/100
Out of the last 20 quarters, PPBT has had 1 profitable quarters and has increased their profits year over year on 0 of them.
NRXP19/100
19/100
Out of the last 20 quarters, NRXP has had 6 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
PPBT48/100
48/100
PPBT has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.
NRXP41/100
41/100
NRXP has had a lower than average amount of volatility over the last 12 months giving it a score of 41 of 100.
Sentiment
PPBT
"Sentiment" not found for PPBT
NRXP69/100
69/100
NRXP had a bullish sentiment score of 69.38% across Twitter and StockTwits over the last 12 months. It had an average of 26.28 posts, 15.67 comments, and 77.44 likes per day.
All score calculations are broken down here to help you make more informed investing decisions
Purple Biotech Ltd. American Depositary Shares Summary
Nasdaq / PPBT
Healthcare
Biotechnology
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
NRX Pharmaceuticals, Inc. Common Stock Summary
Nasdaq / NRXP
Healthcare
Biotechnology
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare PPBT to other companies in the same or a similar industry.